BioWeek

Markets

China's First Oral Obesity Pill Turns the GLP-1 Race Into a Manufacturing Contest

Eli Lilly has won China's first approval for an oral GLP-1 weight-loss drug, beating Novo Nordisk to a market of over half a billion adults. The pill changes the supply economics of obesity care, and the winner will be decided by factory scale.

13 Nov 2026 · 3 min read

Read the story

Sjögren's Went Decades Without an Approved Drug. Two Are Almost Here.

12 Nov 2026

Why the FDA Put a Vision-Loss Warning on Every GLP-1 Label

11 Nov 2026

FDA Approves Asundexian, the First Drug Ever in a New Class of Blood Thinners

10 Nov 2026

Cutting Lp(a) by 78% Did Not Reduce Heart Risk in 8,322 Patients

9 Nov 2026

Biotech Groups Sue Again to Stop Medicare's GLOBE Drug-Pricing Model

8 Nov 2026

Merck and Moderna's Cancer Vaccine Beat Keytruda. The Harder Test Is Manufacturing.

Intismeran plus Keytruda cut melanoma recurrence or death risk by 42% versus Keytruda alone, a first Phase 3 win for a personalized mRNA vaccine. Moderna still fell as much as 25%.

Read the story

Latest

Pipeline

FDA Pushes Mitapivat's Sickle Cell Decision to February Over Liver Safety

5 Nov 2026 · 3 min read

Markets

Lonza Is Buying the Plants Where the Hardest Drugs Get Made

4 Nov 2026 · 3 min read

Pipeline

Huntington's First Disease-Modifying Drug Is Now One FDA Decision Away

3 Nov 2026 · 3 min read

Pipeline

Inovio's First DNA Drug Won Approval on 7 of 26 Patients Avoiding Surgery

2 Nov 2026 · 3 min read

Pipeline

Lilly's Retatrutide More Than Doubled Ozempic's Weight Loss

1 Nov 2026 · 3 min read

Pipeline

Genmab's Antibody Halves Death Risk in Head and Neck Cancer

30 Oct 2026 · 3 min read

Pipeline

See all

Pipeline 19 Oct 2026

Lilly Just Won First-Line CLL With a Drug It Wants to Save for Later

Lilly's Jaypirca just won frontline CLL with a large survival edge, but only over chemoimmunotherapy the field is retiring. Lilly itself says the drug belongs in second line, and that sequencing logic shapes what the new label is really worth.

Anktiva's New Bladder Cancer Approval Runs on Inference, and FDA Says That's the Point

18 Oct 2026

Verastem Bets the Frontline on a Chemotherapy-Free KRAS G12D Regimen

16 Oct 2026

BioNTech's Cancer Vaccine Missed the Endpoint Pembrolizumab Itself Never Won

14 Oct 2026

Markets

See all

Markets 20 Oct 2026

Merck KGaA Pays a 130% Premium for the Second Mover in Polycythemia Vera

Merck KGaA is paying $1.3 billion for a Phase 2 siRNA that has not started Phase 3, entering a polycythemia vera market the FDA opened with Takeda's weekly injection two months ago. The bet rests on quarterly dosing and durable hematocrit control.

Viatris Just Bought Four More Years of EXPAREL Before Its Generic Cliff Arrives

12 Oct 2026

Is Claudin-1 Worth $355 Million Upfront? CSL Just Placed Its Bet

5 Oct 2026

Celcuity Ships Its First Drug Into the Corner of Breast Cancer No PI3K Label Covered

1 Oct 2026

Policy

See all

Policy 15 Oct 2026

FDA Wants Its Rare Disease Flexibility Written Down. The Hard Part Is Where the Lines Land.

With only about 5% of rare conditions carrying an FDA-approved treatment, the agency is trying to turn case-by-case flexibility into written, predictable defaults. Whether that produces certainty or new rigidity is the open question.

PhRMA Sued Over a Rule That Barely Covers Anyone. The Target Is Bigger Than Drug Pricing.

8 Oct 2026

Why the FDA Overrode Its Advisers on Camizestrant

7 Sep 2026

Why uniQure's Huntington Filing Rests on Twelve Patients and Two FDA Reversals

3 Sep 2026

Science

See all

Science 9 Oct 2026

China's First Oral Obesity Pill Turns the GLP-1 Race Into a Manufacturing Contest

Sjögren's Went Decades Without an Approved Drug. Two Are Almost Here.

Why the FDA Put a Vision-Loss Warning on Every GLP-1 Label

FDA Approves Asundexian, the First Drug Ever in a New Class of Blood Thinners

Cutting Lp(a) by 78% Did Not Reduce Heart Risk in 8,322 Patients

Biotech Groups Sue Again to Stop Medicare's GLOBE Drug-Pricing Model

More stories

AstraZeneca’s Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin’s Obesity Pipeline (NASDAQ: PTN)

Zolgensma's Theoretical Cancer Risk Now Has Molecular Proof

The Race to Delete a Protein and Treat Rheumatoid Arthritis

Merck and Moderna's Cancer Vaccine Beat Keytruda. The Harder Test Is Manufacturing.

Latest

FDA Pushes Mitapivat's Sickle Cell Decision to February Over Liver Safety

Lonza Is Buying the Plants Where the Hardest Drugs Get Made

Huntington's First Disease-Modifying Drug Is Now One FDA Decision Away

Inovio's First DNA Drug Won Approval on 7 of 26 Patients Avoiding Surgery

Lilly's Retatrutide More Than Doubled Ozempic's Weight Loss

Genmab's Antibody Halves Death Risk in Head and Neck Cancer

Pipeline

Lilly Just Won First-Line CLL With a Drug It Wants to Save for Later

Anktiva's New Bladder Cancer Approval Runs on Inference, and FDA Says That's the Point

Verastem Bets the Frontline on a Chemotherapy-Free KRAS G12D Regimen

BioNTech's Cancer Vaccine Missed the Endpoint Pembrolizumab Itself Never Won

Markets

Merck KGaA Pays a 130% Premium for the Second Mover in Polycythemia Vera

Viatris Just Bought Four More Years of EXPAREL Before Its Generic Cliff Arrives

Is Claudin-1 Worth $355 Million Upfront? CSL Just Placed Its Bet

Celcuity Ships Its First Drug Into the Corner of Breast Cancer No PI3K Label Covered

Policy

FDA Wants Its Rare Disease Flexibility Written Down. The Hard Part Is Where the Lines Land.

PhRMA Sued Over a Rule That Barely Covers Anyone. The Target Is Bigger Than Drug Pricing.

Why the FDA Overrode Its Advisers on Camizestrant

Why uniQure's Huntington Filing Rests on Twelve Patients and Two FDA Reversals

Science

One Transfer RNA Molecule Controls Whether Prostate Cancer Stays Treatable

Brain Shuttle Platforms Tackle the Blood-Brain Barrier for Genetic Medicines

What tumour-neuron synapses mean for glioblastoma - and why a local siRNA gel is the proposed answer

What blocking Activin A means for FOP - Regeneron’s Pasatru and a disease that turns muscle into bone